Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026

The company said, “In January 2026, Sunshine Biopharma (SBFM) implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company’s focus on achieving near-term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2M to $3M in 2026, although there can be no assurance that these reductions will be fully realized.”